Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours

New E-Learning module by Prof Tessa Brabander is now available. Watch the presentation and take the CME test today!

Learning objectives

  1. To understand essential mechanisms in terms of peptide receptor radionuclide therapy functioning
  2. To understand the role of peptide receptor radionuclide therapy in the management of patients with neuroendocrine tumours
  3. To understand the profile of side effects from the use of peptide receptor radionuclide therapy in the management of patients with neuroendocrine tumours
Title Duration Content CME Points CME Test
Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours 37 min. 51 slides 1 Take test

In this E-Learning module, the author provides essential principles in terms of peptide receptor radionuclide therapy (PPRT) and provides an overview of treatment outcomes and side effects in patients with neuroendocrine tumours (NETs) treated with PPRT. The author argues that all patients with NETs should be evaluated by a multidisciplinary tumour board and PRRT should be considered as a multidisciplinary treatment.

NETs are a rare type of tumours that most frequently originate from the gastrointestinal tract, pancreas and lungs. NETs can produce hormones, thus causing a carcinoid syndrome. The majority of patients present with metastatic disease and 5-year survival rate is approximately 50%.

In this module, the author describes the evolution of the treatment types available for patients with NETs and highlights the treatment goals. The results of pivotal clinical trials with PPRT used in the management of patients with NETs are described in detail. The facts, relevant for the patient selection and clinical practice, are specifically emphasised.

Besides the treatment outcomes described in detail, the author also puts a lot of emphasis on highlighting the toxicities, as well as domains related to quality of life. The author also provides the algorithms for the management of patients with NETs based on recent clinical practice guidelines publications.

The final part of the module is devoted to strategies aimed to optimise PPRT and provides a snapshot of expected new developments in radioligands, receptor expression and combination therapy, making this E-Learning module an excellent opportunity to gain a quick overview of PPRT position in the treatment landscape for patients with NETs and possibility to learn on novel developments in the field.   

Last update: 11 Nov 2021

The author has reported the following financial Interests:
AAA/Novartis, Advisory Board, Institutional
AAA/Novartis, Invited Speaker, Institutional
Ipsen, Invited Speaker, Institutional

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings